Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 88
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl Syndrome mouse model

Transcriptome-guided GLP-1 receptor therapy rescues met...

 98

Methionine restriction and mimetics to ameliorate human aging and disease

Methionine restriction and mimetics to ameliorate human...

 33

Giant extrachromosomal element “Inocle” potentially expands the adaptive capacity of the human oral microbiome

Giant extrachromosomal element “Inocle” potentially exp...

 185